← All organizations
Highest phase reached
Phase 3
First clinical trial
Sep 1, 2012First marketed drug
Jan 23, 2020First NDA
Jan 23, 2020Last known activity
Dec 13, 2023
Acquired by Ipsen on Jun 27, 2022
Timeline
2000s
- Jun 1, 2007
Epizyme, Inc.— Founded
2020s
- Jan 23, 2020
tazemetostat— Marketing Organization
- Jan 23, 2020
tazemetostat— NDA Organization
- Jan 23, 2020
tazemetostat— NDA Secondary Org
- Jun 27, 2022
Ipsen— Acquired By
Drugs by trial phase (30 distinct, 33 trials)
Phase 3 (4 own, 0 via acquisition)
Phase 2 (15 own, 0 via acquisition)
Phase 1 (11 own, 0 via acquisition)
Indications
Studied for
- Carcinoma
- Carcinoma, Medullary
- Carcinoma, Squamous Cell
- Chordoma
- Hematologic Neoplasms
- Kidney Neoplasms
- Leukemia
- Liver Diseases
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Follicular
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Mantle-Cell
- Lymphoma, Non-Hodgkin
- Mesothelioma
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Neoplasms
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Prostatic Neoplasms
- Rhabdoid Tumor
- Sarcoma
- Sarcoma, Synovial
- Squamous Cell Carcinoma of Head and Neck
Marketed drugs (1)
Recent trials (33)
- NCT03874455Lead sponsorN/A—
- NCT04225429Lead sponsorN/A—
- NCT06068881Lead sponsorPhase 2Dec 13, 2023
- NCT05994235CollaboratorPhase 2Nov 1, 2023
- NCT05934838CollaboratorPhase 1Oct 4, 2023
- NCT05551936CollaboratorPhase 1/Phase 2May 31, 2023
- NCT05618366CollaboratorPhase 1Dec 31, 2022
- NCT05407441CollaboratorPhase 1/Phase 2Dec 31, 2022
- NCT05567679CollaboratorEarly Phase 1Nov 30, 2022
- NCT05205252Lead sponsorPhase 1/Phase 2Dec 22, 2021
- NCT05121103Lead sponsorPhase 1Nov 30, 2021
- NCT05023655CollaboratorPhase 2Nov 30, 2021
- NCT04917042CollaboratorPhase 2Aug 24, 2021
- NCT04705818CollaboratorPhase 2Jul 7, 2021
- NCT04846478CollaboratorPhase 1Jun 28, 2021
Details
- Founded
- Cambridge, MA, US Jun 1, 2007
- First NDA
- Jan 23, 2020
- Last known activity
- Dec 13, 2023
Designations held
- Orphan drug
- Priority review
- Accelerated approval